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In its most recent assessment, the American Heart Association (AHA) estimated that in the 
United States alone there were 5.8 million people with heart failure (HF) in 2006 (Lloyd-
Jones, Adams et al. 2010). HF is further estimated to be affecting 23 million people 
worldwide (McMurray, Petrie et al. 1998). Sudden cardiac death (SCD) is the cause of 28-
68% of all mortalities in heart failure patients, the majority of which is due to ventricular 
tachycardia (VT) or ventricular fibrillation (VF) (Engelstein ED 1998). Implanted 
cardioverter-defibrillators (ICDs) have been used for nearly 30 years to effectively stop VT 
or VF, thereby significantly improving sudden cardiac arrhythmic death outcomes in high 
risk patients (DiMarco 2003). Despite the major success of ICDs, implanted patients continue 
to experience VT and VF episodes and a range of possible side effects that make it desirable 
to use ICDs only in situations where necessary.  
Anti-arrhythmic drugs are used to reduce the frequency of ventricular arrhythmias in 
patients with frequent ICD shock. They reduce the ventricular rate of VT so that there is 
better hemodynamic tolerance and more responsiveness to termination by anti-tachycardia 
pacing or low energy cardioversion. These drugs also suppress other arrhythmias that cause 
symptoms or interfere with ICD function and cause "inappropriate" shocks (which may 
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occur in up to 29 percent of ICD patients with substantial impact on their quality of life) 
(Knilans and Prystowsky 1992; Steinberg, Martins et al. 2001). These "inappropriate" shocks 
are caused by a variety of arrhythmias including sinus tachycardia, atrial fibrillation, and 
nonsustained ventricular tachycardia (Pacifico, Hohnloser et al. 1999; Nanthakumar, 
Paquette et al. 2000). However, anti-arrhythmic drugs are not always well tolerated.  
Ultimately, ICD patients are expected to have further arrhythmic episodes and experience 
ICD shocks which, along with the risks of discharge and “inappropriate” shock, can 
significantly and adversely affect the patients’ quality of life. Therefore, it is essential to find 
ways to prevent recurrent episodes of arrhythmias that lead to VT and VF.  
Since the first observation of low risk of cardiac death in the study of Greenland Eskimos 
(Kromann and Green 1980) with high intakes of Omega-3 polyunsaturated fats (PUFAs) 
from sea mammals and fish, Omega-3 PUFAs have been suggested to have potential 
beneficial anti-arrhythmic properties (Burr, Fehily et al. 1989; Armstrong, Wieland et al. 
1994) and hence have been considered for the treatment of high risk patients with 
arrhythmias (especially those at immediate risk, i.e. VT/VF patients). ICD patients, are high 
risk individuals and have been of particular interest in clinical trials investigating the effects 
of PUFAs on ventricular arrhythmias. Because ICDs are capable of terminating arrhythmias 
and recording their occurrence and their specific types, the risk of mortality is greatly 
reduced and the end point which might have resulted in death is averted. Therefore, such 
studies also have the potential to allow for a crossover design (Leaf, Albert et al. 2005; Raitt, 
Connor et al. 2005; Brouwer, Zock et al. 2006). 
But, are Omega-3 PUFAs an appropriate, effective, and sustainable treatment for averting 
VT and VF?  
Randomized controlled trials in ICD patients have produced powerful and illuminating 
data regarding the role of this dietary supplement and could potentially have much to offer 
for other dietary and lifestyle intervention trials. 
2. Ventricular fibrillation and fish 
Sustained ventricular arrhythmias, which include VT and VF, are the most common cause of 
sudden cardiac death (SCD) and are hence considered the most relevant endpoint in regards to 
the harder SCD endpoint when assessing their occurrence using ICDs (Engelstein ED 1998).  
Over the last 6 years, 3 double-blind, placebo controlled, randomized studies have been 
published that used fish oils in patients with ICDs to observe time to first ventricular 
arrhythmia event post ICD implantation (Leaf, Albert et al. 2005; Raitt, Connor et al. 2005; 
Brouwer, Zock et al. 2006). None of these trials successfully demonstrated whether or not 
Omega-3 PUFA supplementation has any preventive effects in ICD patients. These studies 
were first summarized in a meta-analysis by Jenkins et al. (Figure 1) in which they showed a 
small non-significant overall effect with a relative risk of 0.93 [95% CI, 0.70-1.24] when 
comparing the incidence of first ICD discharge in Omega-3 PUFA supplementation versus 
the placebo (Jenkins, Josse et al. 2008). 
Another meta-analysis in the following year confirmed the original findings of Jenkins et al. 
Bouwer et al. showed a non-significant beneficial effect from fish oil in terms of ventricular 
tachyarrhythmias or death when compared to a placebo (Hazard ratio (HR) of 0.90 [95% CI; 
0.67-1.22]) (Brouwer, Raitt et al. 2009). In their sub group analyses, Brouwer and colleagues 
showed that the potential beneficial role of fish oils in ventricular arrhythmias was non-
significant across all subject types: the HR for fish oils vs. placebo in patients with an  
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Fig. 1. Meta-analysis of implantable cardioverter defibrillator discharge in studies of fish-oil 
supplementation. Adapted from Jenkins et al., CMAJ 2008 (Jenkins, Josse et al. 2008). 
ejection fraction (EF) ≤30 was 0.80 [95% CI 0.58-1.12]. In patients with established coronary 
artery disease at baseline, the HR was 0.79 [95% CI 0.6-1.06]. Lastly, in patients with an 
EF>30 the risk was actually increased, though not significantly, with an HR of 1.18 [95% CI 
0.64-2.18].  
Moreover, with further data available to them as the original authors of two of the 
published studies (Brouwer and Raitt); they were also able to pool their data to perform 
more subgroup analyses that showed a range of deleterious outcomes in various subject 
types (Figure 2). Most notably, Brouwer et al. showed significantly higher risk of ventricular 
tachyarrhythmia in patients who used fish oils and were also on lipid-lowering medications 
with an adjusted HR of 1.48 [95% CI 1.01-2.18]. 
 
 
Fig. 2. Hazard ratios of fish oil treatment for time to first ventricular tachyarrhythmia in the 
pooled analyses (Raitt, Connor et al. 2005; Brouwer, Zock et al. 2006) in the entire study 
population (primary analysis) and subgroups (subgroup analyses). Adjustments were made 
for age, gender, ejection fraction, smoking status, New York Heart Association class for 
angina pectoris, New York Heart Association class for dyspnoea, valvular heart disease, 
prior myocardial infarction, cardiomyopathy, ventricular tachycardia as index arrhythmia, 
ventricular fibrillation as index arrhythmia, and use of anti-arrhythmic medication at 
baseline. Adapted from: Brouwer et al., European Heart Journal 2009 (Brouwer, Raitt et al. 
2009). 
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3. Atrial fibrillation and fish 
Although VT and VF are the major concerns with regards to ICD patients, they are not the 
only arrhythmias; for long considered a benign and inconsequential type of arrhythmia, 
Atrial Fibrillation (AF) is now becoming a large concern globally. It is the most common 
arrhythmia in clinical practice, resulting in approximately 1/3 of admissions due to cardiac 
rhythm disturbances. In 1996/1997 alone, the ATRIA investigators estimated 2.3 million 
North Americans to have AF (Go, Hylek et al. 2001). Friberg et al. also illustrated that 
hospital admissions due to AF increased 66% between the late 1970s and late 1990s and 
continue to rise (Friberg, Buch et al. 2003). 
More recently, AF has also been implicated as an independent predictor of VT/VF incidence in 
ICD patients. Stein et al. showed that ICD patients with AF had a multi-variate adjusted HR of 
1.89 [95% CI 1.33-2.69] for VT/VF occurrence in the first year after implantation (Stein, Mittal 
et al. 2009). Similar findings were also produced by other previous trials, including the 
PROFIT and the 'JEWEL-AF-study' (Stein, Euler et al. 2002; Klein, Lissel et al. 2006). 
Fish oils have therefore been proposed as effective in the treatment and prevention of AF. It is 
hypothesized that Omega-3 PUFAs preserve normal electrophysiological function 
(Richardson, Iaizzo et al. 2011). Despite postulated mechanisms, a recent meta-analysis 
suggests that there is much heterogeneity in the current literature and complexity of AF 
pathology. Therefore, these PUFAs require further studies prior to solidly claiming their place 
as a potential therapy. Liu et al. demonstrated that Omega-3 PUFA intake was not significantly 
associated with a reduction in AF episodes (an odds ratio (OR) of 0.81 [95%CI, 0.57-1.15] for 
AF incidence) in patients with established heart disease, such as those who have had a 
coronary artery bypass graft (CABG), persistent AF, or open heart surgery (Liu, 
Korantzopoulos et al. 2011). In an editorial in the same publication (Liu, Korantzopoulos et al. 
2011), Drs. Ramadeen and Dorian elaborated on the reasons why this meta-analysis did not 
show the anticipated outcomes that were observed in the animal studies (Ramadeen and 
Dorian 2011; Richardson, Iaizzo et al. 2011). Dorian et al. discussed the mechanisms by which 
Omega-3 PUFAs can be potentially beneficial may not in fact be due to their antiarrhythmic 
properties (Ramadeen and Dorian 2011) which in other trials have also been questioned since 
in some, Omega-3 PUFAs showed pro-arrhythmic activity (Raitt, Connor et al. 2005), but 
rather due to preventing structural remodelling and fibrosis through their anti-inflammatory 
properties (Ramadeen, Laurent et al. 2010; Saravanan, Davidson et al. 2010). However, for 
Omega-3 PUFAs to have any potential efficacy in patients with arrhythmias, their use must be 
established long before the disease progresses into longer episodes of AF (persistent and 
permanent). Thus, those with existing heart disease may experience no benefit. 
4. Fish oils as the solution 
It can be said with absolute certainty that the collapse of our fish stocks due to overfishing is 
inevitable at the current rate of consumption. Global catches have been declining since the 
late 1980s (Figure 3A) (Watson and Pauly 2001), and the number of collapsed stocks has 
been increasing exponentially since 1950 (Figure 3B) (Worm, Barbier et al. 2006; Costello, 
Gaines et al. 2008). The number and rate of extinctions of marine populations have increased 
catastrophically and will continue. When projected forward these data indicate a complete 
collapse of commercially exploited stocks by 2050 (Pauly, Alder et al. 2003; Worm, Barbier et 
al. 2006). 
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Fig. 3. Global Fishery Trends. (A) Global catch trends from 1950 to 2000, corrected for 
overreporting by China (Watson and Pauly 2001). (B) Stock collapse: Decline to 10% of their 
respective historic maximum yield in fish whose stocks have been exploited (n < 10 000; in 
64 large marine ecosystems) (RFAD-2007; Worm, Barbier et al. 2006; Costello, Gaines et al. 
2008). Adopted from Jenkins et al., CMAJ 2009 (Jenkins, Sievenpiper et al. 2009). 
The current data on ICD patients in the three trials summarized first by the Jenkins et al. 
meta-analysis in 2008 and further investigated by the Brouwer et al. meta-analysis in 2009, 
certainly ascertains the uncertainty of the benefits of fish oils in this population of patients 
with heart disease (Jenkins, Josse et al. 2008; Brouwer, Raitt et al. 2009). Brower et al., further 
elaborates on the potential harms of Omega-3 PUFAs from fish in this population of ICD 
users, from the population of the combined studies of Raitt et al. and Brouwer et al. (Raitt, 
Connor et al. 2005; Brouwer, Zock et al. 2006; Brouwer, Raitt et al. 2009).  
In regards to fish oil benefits for AF prevention, studies show variable results and are 
overall inconclusive (Liu, Korantzopoulos et al. 2011). Despite the proposed 2.5-fold increase 
by 2050 in AF prevalence (Go, Hylek et al. 2001), the lack of certainty on the therapeutic role 
of fish oils contrasts with the certainty that increased fish consumption will simply shorten 
the survival of fish stocks with little or no human health benefit. Therefore, continuing to 
advocate fish consumption to confer health benefits may at present be inappropriate. 
5. Conclusion 
In conclusion, Omega-3 PUFAs may have some potential beneficial effects in heart disease, 
likely not because of having potential anti-arrhythmic effects, as was long postulated, but 
possibly through their anti-inflammatory properties that may in the long term prevent 
structural remodelling, and damage to the electrical conduction pathways of the myocardium 
provided it is initiated before structural remodelling begins (Ramadeen and Dorian 2011). 
However, Omega-3 PUFAs have not been shown to be effective in ICD studies and may 
possibly be harmful in preventing VT/VF episodes after remodelling and fibrosis has occurred 
(Liu, Korantzopoulos et al. 2011; Jenkins, Josse et al. 2008; Brouwer, Raitt et al. 2009).  
To gamble the existence of our planet's fish stocks (Jenkins, Sievenpiper et al. 2009) on 
inconclusive data instead of using lifestyle modifications and appropriate pharmaceutical 
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treatments, that can be as beneficial, is not responsible, both for patients and planetary 
health. It is therefore important to consider the use of other sustainable sources of Omega-3 
PUFAs, such as the recently developed algal sources by Martek and DuPont pharmaceutical 
companies (Arterburn, Oken et al. 2008; Surette 2008), for future exploration of their 
potential benefits in heart disease as well as other diseases.   
Lastly, ICDs in randomized controlled clinical trials have certainly shown their merit in 
assessing the different potential benefits or harms of various treatments, since the discharge 
of implantable cardioverter defibrillators can be used as a surrogate marker for sudden 
death while avoiding death. For example, in the case of fish oils the larger compiled data 
from the Brouwer et al. meta-analysis quite clearly demonstrated some of the unexpected 
harmful effects of high fish oil intake in ICD patients on statin therapy (Brouwer, Raitt et al. 
2009). Ergo, future larger trials with other detailed measurements, including diet and 
lifestyle data, can be used to assess further outcomes and help address controversial 
questions that will form the basis of future guidelines. 
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